• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MHRA, BIA call for earlier access to medicines in the U.K.

MHRA, BIA call for earlier access to medicines in the U.K.

November 18, 2013
CenterWatch Staff

Following the publication of the report on innovation in the regulation of healthcare by the Medicines and Healthcare Products Regulatory Agency (MHRA), the BioIndustry Association (BIA) urges the U.K. government to implement a properly funded and reimbursed Earlier Access to medicines Scheme (EAS), which the group makes its number one recommendation.

“I am pleased that the expert group wants the European Medicines Agency to launch a call for adaptive licensing at the earliest opportunity so  companies could put forward pilot products, and that the group proposes the idea of adopting a new breakthrough designation for new therapies both at a U.K. and E.U. level,” said Steve Bates, BIA’s CEO.

“In just a year since new rules were put in place for the development of treatments in the U.S., 32 drugs have been granted Breakthrough Designation by the FDA,” he said. “This designation has rapidly sped up the process for drugs to become available for patients who need them. These have been for products where there is a desperate need for new drugs, for example in multiple myeloma, cystic fibrosis, hepatitis C, acute heart failure and Duchenne muscular dystrophy. Two drugs with Breakthrough Designation status have already been approved by the FDA.

“If U.K. patients are to benefit from the most promising new drugs and U.K. biotech companies are to develop those therapies here rather than overseas, we need a similar Breakthrough Designation scheme here,” said Bates. “As well as holding the potential to significantly accelerate such treatments to those patients who need them, Breakthrough Designation has had a positive effect on the companies developing the products and on the investment community’s perception of those companies.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing